Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT

Autor: Fiona Collinson, Kara-Louise Royle, Jayne Swain, Christy Ralph, Anthony Maraveyas, Tim Eisen, Paul Nathan, Robert Jones, David Meads, Tze Min Wah, Adam Martin, Janine Bestall, Christian Kelly-Morland, Christopher Linsley, Jamie Oughton, Kevin Chan, Elisavet Theodoulou, Gustavo Arias-Pinilla, Amy Kwan, Luis Daverede, Catherine Handforth, Sebastian Trainor, Abdulazeez Salawu, Christopher McCabe, Vicky Goh, David Buckley, Jenny Hewison, Walter Gregory, Peter Selby, Julia Brown, Janet Brown

Publikováno v: Health Technology Assessment, Vol 28, Iss 45 (2024)

Background There is interest in using treatment breaks in oncology, to reduce toxicity without compromising efficacy. Trial design A Phase II/III multicentre, open-label, parallel-group, randomised controlled non-inferiority trial assessing treatment

Externí odkaz: https://doaj.org/article/f262d31cdee84d25b7afd7439e0362e7

Validation of the HULL Score clinical prediction rule for unsuspected pulmonary embolism in ambulatory cancer patients

Autor: Farzana Haque, Jessamine Ryde, Laura Broughton, Chao Huang, Sifut Sethi, Andrew Stephens, Annet Pillai, Shagufta Mirza, Victoria Brown, Ged Avery, Georgios Bozas, Anthony Maraveyas

Publikováno v: ERJ Open Research, Vol 9, Iss 3 (2023)

Background Clinical prediction rules (CPRs) developed to predict adverse outcomes of suspected pulmonary embolism (PE) and facilitate outpatient management have limitations in discriminating outcomes for ambulatory cancer patients with unsuspected PE

Externí odkaz: https://doaj.org/article/e14c6402c0c4447891f6e6cc738cb028

Deficient DNA mismatch repair and persistence of SARS-CoV-2 RNA shedding: a case report of hereditary nonpolyposis colorectal cancer with COVID-19 infection

Autor: Farzana Haque, Patrick Lillie, Farhana Haque, Anthony Maraveyas

Publikováno v: BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-4 (2021)

Abstract Background Several independent risk factors have been reported to influence viral shedding following COVID-19 infection, but the influence of host-related molecular factors has not yet been described. We report a case of a cancer patient wit

Externí odkaz: https://doaj.org/article/bbf78822f1304a5688402242c982c2a8

Cancer patients' experiences of the diagnosis and treatment of incidental pulmonary embolism (a qualitative study).

Autor: Naima E Benelhaj, Ann Hutchinson, Anthony Maraveyas, Miriam J Johnson

Publikováno v: PLoS ONE, Vol 17, Iss 10, p e0276754 (2022)

BackgroundThe diagnosis of symptomatic cancer-associated thrombosis often causes distress and alarm for patients, especially for those unaware of the risk, or the signs and symptoms to look out for. There are few data about cancer patients' experienc

Externí odkaz: https://doaj.org/article/c708a3d149434ea995c55e3c8e48e778

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Autor: Janet E Brown, Kara-Louise Royle, Walter Gregory, Christy Ralph, Anthony Maraveyas, Omar Din, Timothy Eisen, Paul Nathan, Tom Powles, Richard Griffiths, Robert Jones, Naveen Vasudev, Matthew Wheater, Abdel Hamid, Tom Waddell, Rhona McMenemin, Poulam Patel, James Larkin, Guy Faust, Adam Martin, Jayne Swain, Janine Bestall, Christopher McCabe, David Meads, Vicky Goh, Tze Min Wah, Julia Brown, Jenny Hewison, Peter Selby, Fiona Collinson, Judith Carser, Gopalakrishnan Srinivasan, Fiona Thistlewaite, Ashraf Azzabi, Mark Beresford, David Farrugia, Marios Decatris, Carys Thomas, Joanna Gale, James McAleer, Alison Clayton, Ekaterini Boleti, Thomas Geldart, Santhanam Sundar, Jason Lester, Nachi Palaniappan, Mohan Hingorani, Khaliq Rehman, Mohammad Khan, Naveed Sarwar, Janine Graham, Alastair Thomson, Narayanan Srihari, Denise Sheehan, Rajaguru Srinivasan, Omar Khan, Andrew Stockdale Jane Worlding, Stergios Boussios, Nicholas Stuart, Carey MacDonald-Smith, Falalu Danwata, Duncan McLaren, Aravindhan Sundaramurthy, Anna Lydon, Sharon Beesley, Kathryn Lees, Mohini Varughese, Emma Gray, Angela Scott, Mark Baxter, Anna Mullard, Pasquale Innominato, Gaurav Kapur, Anil Kumar, Natalie Charnley, Caroline Manetta, Prabir Chakraborti, Prantik Das, Sarah Rudman, Henry Taylor, Christos Mikropoulos, Martin Highley, Dakshinamoorthy Muthukumar, Anjali Zarkar, Roy Vergis, Seshadri Sriprasad, Patryk Brulinski, Amanda Clarke, Richard Osbourne, Melanie Harvey, Renata Dega, Geoffrey Sparrow, Urmila Barthakur, Erica Beaumont, Agnieszka Michael, Emilio Porfiri, Faisal Azam, Ravi Kodavtiganti

Publikováno v: STAR Investigators, Brown, J E, Royle, K-L, Gregory, W, Ralph, C, Maraveyas, A, Din, O, Eisen, T, Nathan, P, Powles, T, Griffiths, R, Jones, R, Vasudev, N, Wheater, M, Hamid, A, Waddell, T, McMenemin, R, Patel, P, Larkin, J, Faust, G, Martin, A, Swain, J, Bestall, J, McCabe, C, Meads, D, Goh, V, Min Wah, T, Brown, J, Hewison, J, Selby, P & Collinson, F 2023, ' Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial ', Lancet Oncology, vol. 24, no. 3, pp. 213-227 . https://doi.org/10.1016/S1470-2045(22)00793-8

Temporary drug treatment cessation might alleviate toxicity without substantially compromising efficacy in patients with cancer. We aimed to determine if a tyrosine kinase inhibitor drug-free interval strategy was non-inferior to a conventional conti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a633cdaf72543d0ca87f46d23005d79
https://doi.org/10.1016/s1470-2045(22)00793-8